{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:46:48Z","timestamp":1791406008434,"version":"4.3.3"},"reference-count":158,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute, National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN261200800001E"],"award-info":[{"award-number":["HHSN261200800001E"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.antiviral.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T08:08:28Z","timestamp":1515398908000},"page":"202-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"special_numbering":"C","title":["The role of adjuvant immunomodulatory agents for treatment of severe influenza"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4382-2445","authenticated-orcid":false,"given":"David S.","family":"Hui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-4608","authenticated-orcid":false,"given":"Paul K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4879-4941","authenticated-orcid":false,"given":"John H.","family":"Beigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.01.002_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1086\/656316","article-title":"Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry","volume":"202","author":"Adisasmito","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1086\/655469","article-title":"Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course","volume":"202","author":"Agrati","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib3","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1073\/pnas.0900655106","article-title":"TNF\/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection","volume":"106","author":"Aldridge","year":"2009","journal-title":"Proc Natl Acad Sci U. S. A."},{"key":"10.1016\/j.antiviral.2018.01.002_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/jpet.117.242081","article-title":"Pleiotropic and adverse effects of statins-do epigenetics play a role?","volume":"362","author":"Allen","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.antiviral.2018.01.002_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12931-017-0618-6","article-title":"Sirolimus alters lung pathology and viral load following influenza A virus infection","volume":"18","author":"Alsuwaidi","year":"2017","journal-title":"Respir. Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.antiviral.2013.05.007","article-title":"Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice","volume":"99","author":"Arimori","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013251","article-title":"Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection","volume":"5","author":"Bauer","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib8","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMra1000449","article-title":"Clinical aspects of pandemic influenza a (H1N1) 2009","volume":"362","author":"Bautista","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib9","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1055\/s-0029-1207589","article-title":"Ueber das Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei Thieren","volume":"16","author":"Behring","year":"1890","journal-title":"Dlsch. Med. Wochenschr"},{"key":"10.1016\/j.antiviral.2018.01.002_bib10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S2213-2600(17)30174-1","article-title":"Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study","volume":"5","author":"Beigel","year":"2017","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.03947-14","article-title":"Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro","volume":"59","author":"Belardo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.01.002_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.virol.2013.01.017","article-title":"Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice","volume":"439","author":"Belser","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.01.002_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/rcr2.100","article-title":"Polymyxin-B-immobilized-fiber column hemoperfusion with oseltamivir treatment for ARDS due to influenza H1N1\/09","volume":"3","author":"Binh","year":"2015","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.antiviral.2018.01.002_bib14","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1517\/14728222.2014.902938","article-title":"Protein-based therapies for acute lung injury: targeting neutrophil extracellular traps","volume":"18","author":"Bosmann","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.antiviral.2018.01.002_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jcv.2013.05.011","article-title":"Cytokine responses in patients with mild or severe influenza A(H1N1)pdm09","volume":"58","author":"Bradley-Stewart","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/pds.4112","article-title":"The effect of statins on influenza-like illness morbidity and mortality","volume":"26","author":"Brassard","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.antiviral.2018.01.002_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018120","article-title":"Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease","volume":"6","author":"Brett","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib18","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1164\/rccm.201101-0135OC","article-title":"Early corticosteroids in severe influenza A\/H1N1 pneumonia and acute respiratory distress syndrome","volume":"183","author":"Brun-Buisson","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib19","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1128\/AAC.00219-07","article-title":"Increased survival after gemfibrozil treatment of severe mouse influenza","volume":"51","author":"Budd","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.01.002_bib20","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s00125-005-0102-6","article-title":"Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation","volume":"49","author":"Calkin","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.antiviral.2018.01.002_bib21","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1097\/CCM.0000000000001616","article-title":"Adjuvant corticosteroid treatment in adults with influenza a (H7N9) viral pneumonia","volume":"44","author":"Cao","year":"2016","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011610","article-title":"Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice","volume":"5","author":"Carey","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1099\/jmm.0.47124-0","article-title":"A rationale for using steroids in the treatment of severe cases of A\/H5N1 avian influenza","volume":"56","author":"Carter","year":"2007","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2018.01.002_bib25","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib26","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1073\/pnas.1601911113","article-title":"Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo","volume":"113","author":"Chan","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2018.01.002_bib27","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1086\/338820","article-title":"Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997","volume":"34","author":"Chan","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0140-6736(14)60111-2","article-title":"Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study","volume":"383","author":"Chen","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.01.002_bib29","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/infdis\/jit440","article-title":"Cytokine and chemokine levels in patients infected with the novel avian influenza A (H7N9) virus in China","volume":"208","author":"Chi","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbrc.2017.10.037","article-title":"Mycophenolic mofetil, an alternative antiviral and immunomodulator for the highly pathogenic avian influenza H5N1 virus infection","volume":"494","author":"Cho","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2018.01.002_bib31","doi-asserted-by":"crossref","first-page":"e1003773","DOI":"10.1371\/journal.ppat.1003773","article-title":"Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia","volume":"9","author":"Crotta","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2018.01.002_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071761","article-title":"Mesenchymal stromal (stem) cell therapy fails to improve outcomes in experimental severe influenza","volume":"8","author":"Darwish","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib33","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13054-016-1230-8","article-title":"The influence of corticosteroid treatment on the outcome of influenza A(H1N1pdm09)-related critical illness","volume":"20","author":"Delaney","year":"2016","journal-title":"Crit. Care"},{"key":"10.1016\/j.antiviral.2018.01.002_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1743-422X-4-39","article-title":"Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses","volume":"4","author":"Di Trani","year":"2007","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.01.002_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jinf.2011.12.010","article-title":"Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza","volume":"64","author":"Diaz","year":"2012","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2018.01.002_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/thoraxjnl-2015-208017","article-title":"One-year outcomes of rosuvastatin versus placebo in sepsis-associated acute respiratory distress syndrome: prospective follow-up of SAILS randomised trial","volume":"71","author":"Dinglas","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.antiviral.2018.01.002_bib38","first-page":"2925","article-title":"Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial","volume":"124","author":"Duan","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.antiviral.2018.01.002_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155044","article-title":"Global Variability in Reported Mortality for Critical Illness during the 2009-10 Influenza A(H1N1) Pandemic: a Systematic Review and Meta-Regression to Guide Reporting of Outcomes during Disease Outbreaks","volume":"11","author":"Duggal","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12101","article-title":"Interferon induction and function at the mucosal surface","volume":"255","author":"Durbin","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.antiviral.2018.01.002_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1258\/jrsm.2010.090441","article-title":"The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis","volume":"103","author":"Eyers","year":"2010","journal-title":"J. Roy. Soc. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1750-2659.2009.00090.x","article-title":"Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work","volume":"3","author":"Fedson","year":"2009","journal-title":"Influenza. Respi Viruses"},{"key":"10.1016\/j.antiviral.2018.01.002_bib43","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/039463200702000215","article-title":"N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection","volume":"20","author":"Garozzo","year":"2007","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib45","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bcp.2009.08.025","article-title":"N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus","volume":"79","author":"Geiler","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib46","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib47","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/jmv.23682","article-title":"Simvastatin treatment showed no prophylactic effect in influenza virus-infected mice","volume":"85","author":"Gl\u00fcck","year":"2013","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib48","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201311-2071OC","article-title":"Low titers of serum antibodies inhibiting hemagglutination predict fatal fulminant influenza A(H1N1) 2009 infection","volume":"189","author":"Guihot","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00281-017-0636-y","article-title":"New fronts emerge in the influenza cytokine storm","volume":"39","author":"Guo","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib50","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/jir.2010.0071","article-title":"Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo","volume":"31","author":"Haasbach","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib52","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/cid\/cir398","article-title":"Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection","volume":"53","author":"Han","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib53","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1743-422X-11-70","article-title":"Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice","volume":"11","author":"Hohenadl","year":"2014","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.01.002_bib54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/INF.0b013e3181f127be","article-title":"Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza A virus in intravenous immunoglobulin preparations","volume":"30","author":"Hong","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2018.01.002_bib55","doi-asserted-by":"crossref","first-page":"e32947","DOI":"10.1371\/journal.pone.0032947","article-title":"Critical role of constitutive type I interferon response in bronchial epithelial cell to influenza infection","volume":"7","author":"Hsu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib56","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.clinthera.2015.04.006","article-title":"How did multiple FDA actions affect the utilization and reimbursed costs of thiazolidinediones in US medicaid?","volume":"37","author":"Hsu","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.antiviral.2018.01.002_bib57","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.antiviral.2013.03.019","article-title":"Adjunctive therapies and immunomodulatory agents in the management of severe influenza","volume":"98","author":"Hui","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib58","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib59","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune intravenous immunoglobulin treatment: a multicentre double-blind randomized controlled trial for patients with severe A(H1N1)pdm09 infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.antiviral.2018.01.002_bib60","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.chest.2016.11.012","article-title":"Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb\/III trial","volume":"151","author":"Hung","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.antiviral.2018.01.002_bib61","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.antiviral.2014.09.008","article-title":"In vitro anti-influenza A activity of interferon (IFN)-\u03bb1 combined with IFN-\u03b2 or oseltamivir carboxylate","volume":"111","author":"Ilyushina","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib62","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jinf.2011.12.002","article-title":"Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection","volume":"64","author":"Ishii","year":"2012","journal-title":"J. Infect."},{"key":"10.1016\/j.antiviral.2018.01.002_bib63","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.12685","article-title":"Randomized controlled trial of the effect of regular paracetamol on influenza infection","volume":"21","author":"Jefferies","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.antiviral.2018.01.002_bib157","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.antiviral.2018.01.002_bib155","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/cid\/cix334","article-title":"Preliminary epidemiologic assessment of human infections with highly pathogenic avian influenza A(H5N6) virus, China","volume":"65","author":"Jiang","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib156","article-title":"Chinese medicinal herbs for influenza","volume":"3","author":"Jiang","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.antiviral.2018.01.002_bib64","doi-asserted-by":"crossref","first-page":"e91293","DOI":"10.1371\/journal.pone.0091293","article-title":"Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study","volume":"9","author":"Kakeya","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib65","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.01.002_bib67","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1164\/rccm.201101-0110OC","article-title":"Corticosteroid treatment in critically ill patients with pandemic influenza A\/H1N1 2009 infection: analytic strategy using propensity scores","volume":"183","author":"Kim","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib68","first-page":"245","article-title":"Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010","volume":"6","author":"Kubota-Koketsu","year":"2012","journal-title":"Biologics"},{"key":"10.1016\/j.antiviral.2018.01.002_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032280","article-title":"Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan","volume":"7","author":"Kudo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib70","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.resinv.2012.08.005","article-title":"Clinical preparedness for severe pneumonia with highly pathogenic avian influenza A (H5N1): experiences with cases in Vietnam","volume":"50","author":"Kudo","year":"2012","journal-title":"Respir Investig"},{"key":"10.1016\/j.antiviral.2018.01.002_bib71","doi-asserted-by":"crossref","first-page":"e8087","DOI":"10.1371\/journal.pone.0008087","article-title":"Influenza morbidity and mortality in elderly patients receiving statins: a cohort study","volume":"4","author":"Kwong","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib72","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-152-10-201005180-00017","article-title":"High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia","volume":"152","author":"Lai","year":"2010","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2018.01.002_bib158","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv028","article-title":"Statin treatment and mortality: propensity score-matched analyses of 2007-2008 and 2009-2010 laboratory-confirmed influenza hospitalizations","volume":"2","author":"Laidler","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib73","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3201\/eid1606.100165","article-title":"Invasive aspergillosis after pandemic (H1N1) 2009","volume":"16","author":"Lat","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib74","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/600383","article-title":"Viral loads and duration of viral shedding in adult patients hospitalized with influenza","volume":"200","author":"Lee","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib75","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/thx.2009.130799","article-title":"Outcomes of adults hospitalized with severe influenza","volume":"65","author":"Lee","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.antiviral.2018.01.002_bib76","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3851\/IMP1722","article-title":"Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1)Virus pneumonia","volume":"16","author":"Lee","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.01.002_bib77","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/infdis\/jir187","article-title":"Complications and outcomes of pandemic 2009 influenza a (H1N1) in hospitalized adults \u2013 how are they different from seasonal influenza?","volume":"203","author":"Lee","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib78","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1183\/09031936.00169714","article-title":"Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients","volume":"45","author":"Lee","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.antiviral.2018.01.002_bib79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2017.05.008","article-title":"Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial","volume":"144","author":"Lee","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib80","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.antiviral.2011.07.011","article-title":"Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro","volume":"91","author":"Lee","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib81","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.02335-12","article-title":"Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus","volume":"57","author":"Lejal","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.01.002_bib82","doi-asserted-by":"crossref","first-page":"e107966","DOI":"10.1371\/journal.pone.0107966","article-title":"Avian influenza A H7N9 virus induces severe pneumonia in mice without prior adaptation and responds to a combination of zanamivir and COX-2 inhibitor","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib83","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/irv.12456","article-title":"Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia","volume":"11","author":"Li","year":"2017","journal-title":"Influenza. Respir Viruses"},{"key":"10.1016\/j.antiviral.2018.01.002_bib84","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13287-016-0395-z","article-title":"Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice","volume":"7","author":"Li","year":"2016","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.antiviral.2018.01.002_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19160","article-title":"Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial \u2018in hibernation\u2019, ready for rapid activation","volume":"19","author":"Lim","year":"2015","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.antiviral.2018.01.002_bib86","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1399-6576.2011.02491.x","article-title":"Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland","volume":"55","author":"Linko","year":"2011","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.antiviral.2018.01.002_bib87","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejps.2009.07.004","article-title":"Evaluation of the efficacy and safety of a statin\/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB\/c mice","volume":"38","author":"Liu","year":"2009","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.antiviral.2018.01.002_bib88","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/cid\/cis636","article-title":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09","volume":"55","author":"Louie","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib89","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1465-9921-7-43","article-title":"Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice","volume":"7","author":"Lu","year":"2006","journal-title":"Respir. Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib90","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib91","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00134-010-2078-z","article-title":"Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection","volume":"37","author":"Martin-Loeches","year":"2011","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib92","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00134-013-2829-8","article-title":"Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia","volume":"39","author":"Mart\u00edn-Loeches","year":"2013","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib93","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bcp.2011.05.014","article-title":"N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)","volume":"82","author":"Mata","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib94","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1248\/bpb.31.217","article-title":"Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells","volume":"31","author":"Miyamoto","year":"2008","journal-title":"Biol. Pharmaceut. Bull."},{"key":"10.1016\/j.antiviral.2018.01.002_bib95","doi-asserted-by":"crossref","first-page":"649570","DOI":"10.1155\/2012\/649570","article-title":"Macrolide therapy in respiratory viral infections","volume":"2012","author":"Min","year":"2012","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.antiviral.2018.01.002_bib96","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1093\/jac\/dkw338","article-title":"A review of treatment modalities for Middle East Respiratory Syndrome","volume":"71","author":"Mo","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.01.002_bib97","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.drudis.2015.05.006","article-title":"Sirolimus and everolimus in kidney transplantation","volume":"20","author":"Moes","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2018.01.002_bib98","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1164\/rccm.201701-0170OC","article-title":"Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer","volume":"196","author":"Morrison","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib99","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3851\/IMP2080","article-title":"Inhibition of influenza A virus replication by antagonism of a PI3K-AKT-mTOR pathway member identified by gene-trap insertional mutagenesis","volume":"22","author":"Murray","year":"2012","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.01.002_bib100","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.antiviral.2018.01.002_bib101","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1401520","article-title":"Rosuvastatin for sepsis-associated acute respiratory distress syndrome","volume":"370","author":"Truwit","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib102","first-page":"23","article-title":"Neutralizing activities against seasonal influenza viruses in human intravenous immunoglobulin","volume":"11","author":"Onodera","year":"2017","journal-title":"Biologics"},{"key":"10.1016\/j.antiviral.2018.01.002_bib103","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1743-422X-3-39","article-title":"In vitro inhibition of human influenza A virus replication by chloroquine","volume":"3","author":"Ooi","year":"2006","journal-title":"Virol. J."},{"key":"10.1016\/j.antiviral.2018.01.002_bib104","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1001\/jama.2013.280031","article-title":"Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial","volume":"310","author":"Papazian","year":"2013","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.antiviral.2018.01.002_bib105","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.antiviral.2018.01.002_bib106","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PCC.0b013e3181e2a569","article-title":"Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza-An associated respiratory failure and hemodynamic shock","volume":"12","author":"Patel","year":"2011","journal-title":"Pediatr. Crit. Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib107","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1473-3099(11)70065-2","article-title":"Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial","volume":"11","author":"Paton","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib108","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(04)15595-5","article-title":"Re-emergence of fatal human influenza A subtype H5N1 disease","volume":"363","author":"Peiris","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.01.002_bib109","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/qjmed\/hcs112","article-title":"Incidence of serious side effects with intravenous bisphosphonate: a clinical audit","volume":"105","author":"Powell","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.antiviral.2018.01.002_bib110","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/infdis\/jis253","article-title":"Phenotypic and functional characterization of human \u03b3\u03b4 T-cell subsets in response to influenza A viruses","volume":"205","author":"Qin","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib111","doi-asserted-by":"crossref","first-page":"e35788","DOI":"10.1371\/journal.pone.0035788","article-title":"The effect of rosuvastatin in a murine model of influenza A infection","volume":"7","author":"Radigan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib112","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib113","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1164\/rccm.200604-561OC","article-title":"Cigarette smoke impacts immune inflammatory responses to influenza in mice","volume":"174","author":"Robbins","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib114","first-page":"119","article-title":"Intravenous immunoglobulin protects against severe pandemic influenza infection","volume":"19","author":"Rockman","year":"2017","journal-title":"EBio Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib115","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza","volume":"3","author":"Rodrigo","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.antiviral.2018.01.002_bib116","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/cc13912","article-title":"Polymyxin B hemoperfusion: a mechanistic perspective","volume":"18","author":"Ronco","year":"2014","journal-title":"Crit. Care"},{"key":"10.1016\/j.antiviral.2018.01.002_bib117","doi-asserted-by":"crossref","first-page":"29798","DOI":"10.1074\/jbc.M109.029470","article-title":"Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level","volume":"284","author":"Rossignol","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2018.01.002_bib118","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib119","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2018.01.002_bib120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.antiviral.2018.01.002_bib121","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1359\/jbmr.06s218","article-title":"Medical management of Paget's disease of bone: indications for treatment and review of current therapies","volume":"21","author":"Siris","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib122","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.antiviral.2018.01.002_bib123","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/ciu887","article-title":"Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys","volume":"60","author":"Sun","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib124","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s00134-010-1830-8","article-title":"Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion","volume":"36","author":"Takeda","year":"2010","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib125","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib126","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/resp.13047","article-title":"Mucoactive agents for chronic, non-cystic fibrosis lung disease: a systematic review and meta-analysis","volume":"22","author":"Tarrant","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.antiviral.2018.01.002_bib127","doi-asserted-by":"crossref","first-page":"803","DOI":"10.21037\/jtd.2016.03.29","article-title":"Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China","volume":"8","author":"Tian","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib128","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/1096-9071(200103)63:3<242::AID-JMV1007>3.0.CO;2-N","article-title":"Pathology of fatal human infection associated with avian influenza A H5N1 virus","volume":"63","author":"To","year":"2001","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib129","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1086\/650581","article-title":"Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection","volume":"50","author":"To","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib130","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1099\/jgv.0.000512","article-title":"Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans","volume":"97","author":"To","year":"2016","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib131","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/vaccines3010172","article-title":"Emerging influenza strains in the last two decades: a threat of a new pandemic?","volume":"3","author":"Trombetta","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.antiviral.2018.01.002_bib132","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.20110226","article-title":"The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a gammadelta T cell population in humanized mice","volume":"208","author":"Tu","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib133","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","article-title":"Evaluation of convalescent plasma for Ebola virus disease in Guinea","volume":"374","author":"van Griensven","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib134","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/infdis\/jir695","article-title":"Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study","volume":"205","author":"Vandermeer","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1750-2659.2007.00027.x","article-title":"Chloroquine is effective against influenza A virus in vitro but not in vivo","volume":"1","author":"Vigerust","year":"2007","journal-title":"Influenza. Respir Viruses"},{"key":"10.1016\/j.antiviral.2018.01.002_bib136","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1358\/dot.2009.45.7.1384878","article-title":"Mycophenolate mofetil: an update","volume":"45","author":"Villarroel","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.antiviral.2018.01.002_bib137","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib138","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.antiviral.2018.01.002_bib139","doi-asserted-by":"crossref","first-page":"217","DOI":"10.7326\/0003-4819-155-4-201108160-00005","article-title":"Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial","volume":"155","author":"Wang","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CCM.0b013e3182a2727d","article-title":"Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure","volume":"42","author":"Wang","year":"2014","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib141","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2213-2600(13)70221-2","article-title":"Human infection with avian influenza A H6N1 virus: an epidemiological analysis","volume":"1","author":"Wei","year":"2013","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib159","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/89058","article-title":"Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site","volume":"7","author":"Weitz-Schmidt","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib142","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/infdis\/jiw603","article-title":"Acute respiratory infection and use of nonsteroidal anti-inflammatory drugs on risk of acute myocardial infarction: a nationwide case-crossover study","volume":"215","author":"Wen","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib143","series-title":"WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009 Influenza and Other Influenza Viruses","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.antiviral.2018.01.002_bib144","series-title":"Influenza (Seasonal) Fact Sheet","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.antiviral.2018.01.002_bib145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijid.2015.10.009","article-title":"Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma","volume":"41","author":"Wu","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.01.002_bib146","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/jpet.109.162149","article-title":"Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells","volume":"333","author":"Yamaya","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.antiviral.2018.01.002_bib147","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/cr.2012.165","article-title":"Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model","volume":"23","author":"Yan","year":"2013","journal-title":"Cell Res."},{"key":"10.1016\/j.antiviral.2018.01.002_bib148","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1508375","article-title":"Acetaminophen for fever in critically ill patients with suspected infection","volume":"373","author":"Young","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib149","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.01.002_bib150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2014.06.013","article-title":"N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury","volume":"22","author":"Zhang","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.antiviral.2018.01.002_bib151","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1073\/pnas.0711942105","article-title":"Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A\/H5N1 virus","volume":"105","author":"Zheng","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.antiviral.2018.01.002_bib152","article-title":"The therapeutic effect of pamidronate on lethal avian influenza a H7N9 virus infected humanized mice","volume":"10","author":"Zheng","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.01.002_bib153","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza A (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2018.01.002_bib154","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature12379","article-title":"Biological features of novel avian influenza A (H7N9) virus","volume":"499","author":"Zhou","year":"2013","journal-title":"Nature"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217307362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T13:05:17Z","timestamp":1693400717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217307362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":158,"alternative-id":["S0166354217307362"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.01.002","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of adjuvant immunomodulatory agents for treatment of severe influenza","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}